Carl H. June

144.2k total citations · 55 hit papers
657 papers, 85.8k citations indexed

About

Carl H. June is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Carl H. June has authored 657 papers receiving a total of 85.8k indexed citations (citations by other indexed papers that have themselves been cited), including 411 papers in Oncology, 338 papers in Immunology and 176 papers in Molecular Biology. Recurrent topics in Carl H. June's work include CAR-T cell therapy research (381 papers), Immune Cell Function and Interaction (217 papers) and T-cell and B-cell Immunology (143 papers). Carl H. June is often cited by papers focused on CAR-T cell therapy research (381 papers), Immune Cell Function and Interaction (217 papers) and T-cell and B-cell Immunology (143 papers). Carl H. June collaborates with scholars based in United States, Switzerland and Germany. Carl H. June's co-authors include Bruce L. Levine, David L. Porter, Michael Kalos, James L. Riley, Stephan A. Grupp, Craig B. Thompson, Michael C. Milone, David C. Fajgenbaum, Adam Bagg and Michel Sadelain and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Carl H. June

645 papers receiving 84.1k citations

Hit Papers

Chimeric Antigen Receptor T... 1989 2026 2001 2013 2014 2011 2013 2018 2019 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
    2014 3.9k citations Anne Chew, Simon F. Lacey et al. profile →
  2. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
    2011 2.7k citations Bruce L. Levine, Michael Kalos et al. profile →
  3. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
    2013 2.6k citations Stephan A. Grupp, Michael Kalos et al. profile →
  4. CAR T cell immunotherapy for human cancer
    2018 2.1k citations Carl H. June, Omkar U. Kawalekar et al. profile →
  5. Delivery technologies for cancer immunotherapy
    2019 2.0k citations Carl H. June et al. profile →
  6. Cytokine Storm
    2020 2.0k citations Carl H. June et al. profile →
  7. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
    2011 1.8k citations Michael Kalos, Bruce L. Levine et al. profile →
  8. Chimeric Antigen Receptor Therapy
    2018 1.5k citations Carl H. June et al. profile →
  9. A human memory T cell subset with stem cell–like properties
    2011 1.4k citations Chrystal M. Paulos, Carmine Carpenito et al. profile →
  10. Cytokine release syndrome in severe COVID-19
    2020 1.3k citations Carl H. June et al. profile →
  11. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
    2015 1.3k citations Simon F. Lacey, Stephan A. Grupp et al. profile →
  12. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
    2017 1.3k citations Stephen J. Schuster, Mariusz A. Wasik et al. profile →
  13. The B7 and CD28 receptor families
    1994 1.1k citations Carl H. June et al. profile →
  14. The CD28 Signaling Pathway Regulates Glucose Metabolism
    2002 1.1k citations James L. Riley, Carl H. June et al. profile →
  15. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
    2014 973 citations Michael Kalos, Gabriela Plesa et al. profile →
  16. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation
    2004 927 citations Carl H. June, James L. Riley et al. profile →
  17. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    2001 913 citations George Coukos, Carl H. June et al. profile →
  18. Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
    2009 893 citations Michael C. Milone, Carmine Carpenito et al. profile →
  19. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
    2016 887 citations Omkar U. Kawalekar, Joseph A. Fraietta et al. profile →
  20. Engineered T cells: the promise and challenges of cancer immunotherapy
    2016 816 citations Carl H. June, Bruce L. Levine et al. profile →
  21. Regulation of Lymphokine Messenger RNA Stability by a Surface-Mediated T Cell Activation Pathway
    1989 815 citations Carl H. June et al. profile →
  22. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
    2010 805 citations Claudio G. Brunstein, Jeffrey S. Miller et al. Blood profile →
  23. The Principles of Engineering Immune Cells to Treat Cancer
    2017 783 citations Carl H. June et al. profile →
  24. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
    2016 738 citations Xiaojun Liu, Chongyun Fang et al. Clinical Cancer Research profile →
  25. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
    2013 693 citations Gregory L. Beatty, Andrew R. Haas et al. Cancer Immunology Research profile →
  26. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
    2009 690 citations Carmine Carpenito, Michael C. Milone et al. profile →
  27. Role of the CD28 receptor in T-cell activation
    1990 579 citations Carl H. June et al. profile →
  28. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.
    1989 566 citations Carl H. June et al. profile →
  29. Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation
    2002 549 citations Richard G. Carroll, James L. Riley et al. profile →
  30. Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
    2013 515 citations Liang‐Chuan S. Wang, Albert Lo et al. Cancer Immunology Research profile →
  31. Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
    2012 502 citations John Scholler, Gabriela Plesa et al. profile →
  32. Antibody-modified T cells: CARs take the front seat for hematologic malignancies
    2014 490 citations Marcela V. Maus, Stephan A. Grupp et al. Blood profile →
  33. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
    2018 478 citations J. Joseph Melenhorst, Simon F. Lacey et al. profile →
  34. T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
    2013 476 citations Marcela V. Maus, Andrew R. Haas et al. Cancer Immunology Research profile →
  35. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
    2020 453 citations Nathan Singh, Carl H. June et al. profile →
  36. Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
    2011 447 citations Edmund K. Moon, Carmine Carpenito et al. Clinical Cancer Research profile →
  37. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
    2015 434 citations Alfred L. Garfall, Marcela V. Maus et al. profile →
  38. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
    2018 430 citations Sònia Guedan, Avery D. Posey et al. profile →
  39. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
    2015 425 citations Xiaojun Liu, Shuguang Jiang et al. Cancer Research profile →
  40. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
    2016 420 citations Xiaojun Liu, Raghuveer Ranganathan et al. Cancer Research profile →
  41. Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
    2015 407 citations Albert Lo, Liang‐Chuan S. Wang et al. Cancer Research profile →
  42. Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
    2017 400 citations Regina M. Young, John Scholler et al. profile →
  43. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
    2018 379 citations Gregory L. Beatty, Simon F. Lacey et al. profile →
  44. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
    2016 344 citations Simon F. Lacey, J. Joseph Melenhorst et al. profile →
  45. Ibrutinib treatment improves T cell number and function in CLL patients
    2017 288 citations Joseph A. Fraietta, Carl H. June et al. profile →
  46. CAR T therapy beyond cancer: the evolution of a living drug
    2023 286 citations Carl H. June et al. profile →
  47. Nanomaterials for T-cell cancer immunotherapy
    2021 250 citations Neil C. Sheppard, Carl H. June et al. profile →
  48. Engineered cellular immunotherapies in cancer and beyond
    2022 192 citations Carl H. June et al. profile →
  49. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
    2024 132 citations Bruce L. Levine, Stephan A. Grupp et al. profile →
  50. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors
    2023 129 citations Zebin Xiao, Leslie Todd et al. profile →
  51. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
    2023 104 citations Tong Da, Marco Ruella et al. profile →
  52. Advancements and challenges in CAR T cell therapy in autoimmune diseases
    2024 85 citations Carl H. June et al. profile →
  53. Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
    2023 66 citations Neil C. Sheppard, Carl H. June et al. profile →
  54. Beyond the blood: expanding CAR T cell therapy to solid tumors
    2024 56 citations Carl H. June et al. profile →
  55. From concept to cure: The evolution of CAR-T cell therapy
    2025 28 citations Carl H. June et al. profile →

Peers

Carl H. June
Comparison fields: 5 of 182
  • Oncology 52.4k
  • Immunology 40.7k
  • Molecular Biology 24.4k
  • Genetics 16.4k
  • Biomedical Engineering 14.0k
Replace Steven A. Rosenberg with:
Steven A. Rosenberg United States
Nicholas P. Restifo United States
Michel Sadelain United States
Mark J. Smyth Australia
Drew M. Pardoll United States
Laurence Zitvogel France
Gordon J. Freeman United States
Steven Μ. Albelda United States
Stephen J. Forman United States
Jedd D. Wolchok United States
Steven A. Rosenberg United States View profile →
Citations per field, relative to Carl H. June
Carl H. June · 1×
Citations per year, relative to Carl H. June
Carl H. June · 1×

Countries citing papers authored by Carl H. June

Since Specialization
Citations

This map shows the geographic impact of Carl H. June's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl H. June with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl H. June more than expected).

Fields of papers citing papers by Carl H. June

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl H. June. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl H. June. The network helps show where Carl H. June may publish in the future.

Co-authorship network of co-authors of Carl H. June

This figure shows the co-authorship network connecting the top 25 collaborators of Carl H. June. A scholar is included among the top collaborators of Carl H. June based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl H. June. Carl H. June is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors
2023 ·Cancer Research ·Wenqun Zhong, Zebin Xiao, (unknown), (unknown), (unknown), Ziyan Yu, (unknown), Neil C. Sheppard, Serge Y. Fuchs, Xiaowei Xu, Meenhard Herlyn, Carl H. June, Ellen Puré, Wei Guo
39
2
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74
2022 ·Clinical Cancer Research ·(unknown), Estela Noguera-Ortega, Zebin Xiao, Leslie Todd, John Scholler, Decheng Song, Maria Liousia, (unknown), Kexiang Xu, Kimberly J. Edwards, Michael D. Farwell, Carl H. June, Steven Μ. Albelda, Ellen Puré, Mark A. Sellmyer
34
3
The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
2021 ·Clinical Cancer Research ·(unknown), Adam D. Cohen, Simon F. Lacey, Megan M. Davis, Alfred L. Garfall, J. Joseph Melenhorst, Russell Maxwell, W. Tristram Arscott, Amit Maity, Joshua Jones, John P. Plastaras, Edward A. Stadtmauer, Bruce L. Levine, Carl H. June, Michael C. Milone, Ima Paydar
23
4
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
2020 ·Blood ·Xin He, Zijie Feng, Jian Ma, Sunbin Ling, Yan Cao, Buddha Gurung, Yuan Wu, Bryson W. Katona, (unknown), Don L. Siegel, Carl H. June, Xianxin Hua
155
5
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager
2018 ·Cancer Immunology Research ·Anna Wing, Carlos Alberto Fajardo, Avery D. Posey, Carolyn E. Shaw, Tong Da, Regina M. Young, Ramón Alemany, Carl H. June, Sònia Guedan
204
6
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
2017 ·Cancer Discovery ·Marco Ruella, Michael Klichinsky, Saad S. Kenderian, Olga Shestova, Amy Ziober, (unknown), Michael D. Feldman, Mariusz A. Wasik, Carl H. June, Saar Gill
153
7
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors breakdown →
2016 ·Cancer Research ·Xiaojun Liu, Raghuveer Ranganathan, Shuguang Jiang, Chongyun Fang, Jing Sun, Soyeon Kim, Kheng Newick, Albert Lo, Carl H. June, Yangbing Zhao, Edmund K. Moon
420
8
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
2016 ·Clinical Cancer Research ·Marco Ruella, Saad S. Kenderian, Olga Shestova, Joseph A. Fraietta, Sohail Qayyum, Qian Zhang, Marcela V. Maus, Xiaobin Liu, Selene Nuñez-Cruz, Michael Klichinsky, Omkar U. Kawalekar, Michael C. Milone, Simon F. Lacey, Anthony R. Mato, Stephen J. Schuster, Michael Kalos, Carl H. June, Saar Gill, Mariusz A. Wasik
141
9
Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect
2015 ·Blood ·Claudio G. Brunstein, Jeffrey S. Miller, David H. McKenna, Keli L. Hippen, Todd E. DeFor, Darin Sumstad, Julie Curtsinger, Michael R. Verneris, Margaret L. MacMillan, Bruce L. Levine, James L. Riley, Carl H. June, Chap T. Le, Daniel J. Weisdorf, Philip B. McGlave, Bruce R. Blazar, John E. Wagner
303
10
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy
2015 ·Clinical Cancer Research ·Emese Zsíros, Priyanka Duttagupta, Denarda Dangaj Laniti, Hongzhe Li, Renee Frank, Thomas Garrabrant, Ian S. Hagemann, Bruce L. Levine, Carl H. June, Lin Zhang, Ena Wang, Francesco M. Marincola, Davide Bedognetti, Daniel J. Powell, János L. Tanyi, Michael D. Feldman, Lana E. Kandalaft, George Coukos
48
11
Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma
2014 ·Cancer Immunology Research ·Nathan Singh, Xiaojun Liu, Jessica Hulitt, Shuguang Jiang, Carl H. June, Stephan A. Grupp, David M. Barrett, Yangbing Zhao
65
12
Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
2013 ·Cancer Research ·Matthew J. Riese, Liang‐Chuan S. Wang, Edmund K. Moon, Rohan P. Joshi, Anjana Ranganathan, Carl H. June, Gary A. Koretzky, Steven Μ. Albelda
106
13
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
2013 ·Cancer Immunology Research ·Evripidis Lanitis, Mathilde Poussin, Alex W. Klattenhoff, De-Gang Song, Raphael Sandaltzopoulos, Carl H. June, Daniel J. Powell
285
14
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies breakdown →
2013 ·Cancer Immunology Research ·Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus, Drew A. Torigian, Michael C. Soulen, Gabriela Plesa, Anne Chew, Yangbing Zhao, Bruce L. Levine, Steven Μ. Albelda, Michael Kalos, Carl H. June
693
15
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor breakdown →
2011 ·Clinical Cancer Research ·Edmund K. Moon, Carmine Carpenito, Jing Sun, Liang‐Chuan S. Wang, Veena Kapoor, Jarrod D. Predina, Daniel J. Powell, James L. Riley, Carl H. June, Steven Μ. Albelda
447
16
Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer
2011 ·Clinical Cancer Research ·Nancy M. Hardy, Miriam E. Mossoba, Seth M. Steinberg, Vicki Fellowes, Xiaoyi Yan, Frances T. Hakim, Rebecca Babb, Daniele Avila, Juan Gea‐Banacloche, Claude Sportès, Bruce L. Levine, Carl H. June, (unknown), Ashley Carpenter, Michael Krumlauf, Andrew J. Dwyer, Ronald E. Gress, Daniel H. Fowler, Michael Bishop
12
17
In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
2011 ·Cancer Research ·(unknown), Qunrui Ye, Carmine Carpenito, Mathilde Poussin, Liping Wang, Chunyan Ji, Mariangela Figini, Carl H. June, George Coukos, Daniel J. Powell
237
18
Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
2010 ·Cancer Research ·Yangbing Zhao, Edmund K. Moon, Carmine Carpenito, Chrystal M. Paulos, Xiaojun Liu, Andrea Brennan, Anne Chew, Richard G. Carroll, John Scholler, Bruce L. Levine, Steven Μ. Albelda, Carl H. June
366
19
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
2010 ·Blood ·Qing Zhou, Meghan E. Munger, Steven L. Highfill, Jakub Tolar, Brenda J. Weigel, Megan Riddle, Arlene H. Sharpe, Daniel A. Vallera, Miyuki Azuma, Bruce L. Levine, Carl H. June, William J. Murphy, David H. Munn, Bruce R. Blazar
230
20
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics breakdown →
2010 ·Blood ·Claudio G. Brunstein, Jeffrey S. Miller, Qing Cao, David H. McKenna, Keli L. Hippen, Julie Curtsinger, Todd E. DeFor, Bruce L. Levine, Carl H. June, Pablo Rubinstein, Philip B. McGlave, Bruce R. Blazar, John E. Wagner
805

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven A. Rosenberg Breakdown of academic impact, for papers by Nicholas P. Restifo Breakdown of academic impact, for papers by Michel Sadelain Breakdown of academic impact, for papers by Mark J. Smyth Breakdown of academic impact, for papers by Drew M. Pardoll Breakdown of academic impact, for papers by Laurence Zitvogel Breakdown of academic impact, for papers by Gordon J. Freeman Breakdown of academic impact, for papers by Steven Μ. Albelda Breakdown of academic impact, for papers by Stephen J. Forman Breakdown of academic impact, for papers by Jedd D. Wolchok
Rankless by CCL
2026